Analysis of oncology research from 2001 to 2010: a scientometric perspective.

Over the past half-century, the incidence of tumours has increased, resulting in cancer becoming one of the most lethal diseases in humans. In the present study, we elucidated the status of oncology research from 2001 to 2010. Studies published in 30 representative oncology journals were retrieved from the Web of Science (2001-2010) to compose our dataset. Knowledge domain visualisation, co-citation analysis and social network analysis methods were used. By mapping the oncology research performed from 2001 to 2010, we identified the primary research centres, including the top 20 institutions and countries and the 4 major oncology research fronts: i) the mechanism of abnormal oncogene expression; ii) tumour metastasis and angiogenesis; iii) the relationship between cancer cells and apoptosis; and iv) tumour vaccines. We also identified the 36 most collaborative academic communities, and multiple myeloma, angiogenesis and acute lymphocytic leukaemia were found to be the focuses of collaborative research in oncology from 2001 to 2010. Over the past 10 years, America has led oncology research, while China is the sole developing country to be ranked in the top 10. Analyses of the main research centres and forefronts may assist researchers in addressing these forefronts and ascertaining the developing trends in oncology. Analysis of the academic communities performing oncology research may provide scientific evidence and suggestions for policymakers to select the most prolific academic groups and leaders and to effectively manage and finance future oncology research. These selected groups and individuals will carry out additional joint undertakings and solve complex problems encountered in oncology research.

[1]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[2]  Chaomei Chen,et al.  Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace , 2012, Expert opinion on biological therapy.

[3]  Maria R. Lee,et al.  Revealing research themes and trends in knowledge management: From 1995 to 2010 , 2012, Knowl. Based Syst..

[4]  Qi Yu,et al.  Research groups of oncology co-authorship network in China , 2011, Scientometrics.

[5]  Qingqiang Wu,et al.  Co-word analysis of the trends in stem cells field based on subject heading weighting , 2011, Scientometrics.

[6]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[7]  Ju Wang,et al.  Visualizing the research on pervasive and ubiquitous computing , 2011, Scientometrics.

[8]  Leanne Bowler,et al.  The self-regulation of curiosity and interest during the information search process of adolescent students , 2010 .

[9]  C. Morel,et al.  Co-authorship Network Analysis: A Powerful Tool for Strategic Planning of Research, Development and Capacity Building Programs on Neglected Diseases , 2009, PLoS neglected tropical diseases.

[10]  Yuqiang Feng,et al.  A measure of authors’ centrality in co-authorship networks based on the distribution of collaborative relationships , 2009, Scientometrics.

[11]  Cédric Gossart,et al.  Co-authorship networks in social sciences: The case of Turkey , 2009, Scientometrics.

[12]  C. Kindler,et al.  Active Research Fields in Anesthesia: A Document Co-Citation Analysis of the Anesthetic Literature , 2008, Anesthesia and analgesia.

[13]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[14]  M. Blasco,et al.  Cellular Senescence in Cancer and Aging , 2007, Cell.

[15]  Chaomei Chen,et al.  Web site design with the patron in mind: A step-by-step guide for libraries , 2006 .

[16]  Bo Jarneving,et al.  A comparison of two bibliometric methods for mapping of the research front , 2005, Scientometrics.

[17]  Chaomei Chen,et al.  Visualizing knowledge domains , 2005, Annu. Rev. Inf. Sci. Technol..

[18]  Chaomei Chen,et al.  Mapping Scientometrics (1981-2001) , 2005, ASIST.

[19]  Nicoleta C. Arva,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[20]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[22]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[23]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[24]  Daniel Jones Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[25]  Chaomei Chen,et al.  Searching for intellectual turning points: Progressive knowledge domain visualization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Timothy Cribbin,et al.  Visualizing and tracking the growth of competing paradigms: Two case studies , 2002, J. Assoc. Inf. Sci. Technol..

[27]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[28]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[29]  D. Hanahan,et al.  Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer , 2002, BMC Cancer.

[30]  J. Sambrook,et al.  Dominant negative ATM mutations in breast cancer families. , 2002, Journal of the National Cancer Institute.

[31]  Stephen N. Jones,et al.  p53 mutant mice that display early ageing-associated phenotypes , 2002, Nature.

[32]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[33]  Ronit Vogt Sionov,et al.  The cellular response to p53: the decision between life and death , 1999, Oncogene.

[34]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[35]  K. Kinzler,et al.  14-3-3σ is required to prevent mitotic catastrophe after DNA damage , 1999, Nature.

[36]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[37]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[38]  Junying Yuan,et al.  Solution Structure of BID, an Intracellular Amplifier of Apoptotic Signaling , 1999, Cell.

[39]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[40]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[41]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[42]  A. Blann,et al.  Evidence of platelet activation in hypertension , 1997, Journal of Human Hypertension.

[43]  J. Herman,et al.  DNA methylation changes in hematologic malignancies: biologic and clinical implications. , 1997, Leukemia.

[44]  J. S. Katz,et al.  What is research collaboration , 1997 .

[45]  M. Sy,et al.  Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. , 1994, Science.

[46]  Henry G. Small,et al.  Co-citation in the scientific literature: A new measure of the relationship between two documents , 1973, J. Am. Soc. Inf. Sci..

[47]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[48]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[49]  Wang Hai-li The Role of SNAIL Gene in Gynecologic Cacinoma Metastasis Mechanism , 2010 .

[50]  Xu Hui-fa Apoptosis of Osteosarcoma Cells Induced by a Combination of TRAIL,Adriamycin and IFN-γ , 2010 .

[51]  L. Jun-sheng Clinical significance of the expression of ADAM9 in colon carcer , 2009 .

[52]  Chen Yue,et al.  The rise of mapping knowledge domain , 2005 .

[53]  A. Chapelle,et al.  Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability , 1995, Nature Genetics.